Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
From - Diagnostic Testing & Emerging Technologies
The American Society of Clinical Oncology endorsed the American Pathologists' practice guidelines for human papillomavirus (HPV) testing in…
From - Diagnostic Testing & Emerging Technologies
A laboratory-initiated, online effort to reach cancer patients' relatives coupled with discounted genetic tests can increase rates of cascade testing, according to…
From - Diagnostic Testing & Emerging Technologies
Prenatal diagnostics have evolved from conventional cytogenetic analysis to increasingly chromosomal microarray analysis, within the last…
From - Diagnostic Testing & Emerging Technologies
Tumor markers alone may be adequate to monitor for relapse among children and teens with malignant germ cell tumors (MGCTs), according to a study published…
From - Diagnostic Testing & Emerging Technologies
Point-of-care (POC) HbA1c measurements show a high level of agreement with central laboratory test in the outpatient setting…